Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Oxford University Press Country of Publication: England NLM ID: 7802871 Publication Model: Print Cited Medium: Internet ISSN: 1464-3685 (Electronic) Linking ISSN: 03005771 NLM ISO Abbreviation: Int J Epidemiol Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] Oxford University Press.
    • الموضوع:
      COVID-19*/epidemiology ; COVID-19*/prevention & control ; Smallpox Vaccine*; Humans ; BNT162 Vaccine ; COVID-19 Vaccines ; Northern Ireland/epidemiology ; Wales/epidemiology ; SARS-CoV-2 ; Vaccination ; England ; Scotland
    • نبذة مختصرة :
      Background: Several SARS-CoV-2 vaccines have been shown to provide protection against COVID-19 hospitalization and death. However, some evidence suggests that notable waning in effectiveness against these outcomes occurs within months of vaccination. We undertook a pooled analysis across the four nations of the UK to investigate waning in vaccine effectiveness (VE) and relative vaccine effectiveness (rVE) against severe COVID-19 outcomes.
      Methods: We carried out a target trial design for first/second doses of ChAdOx1(Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) with a composite outcome of COVID-19 hospitalization or death over the period 8 December 2020 to 30 June 2021. Exposure groups were matched by age, local authority area and propensity for vaccination. We pooled event counts across the four UK nations.
      Results: For Doses 1 and 2 of ChAdOx1 and Dose 1 of BNT162b2, VE/rVE reached zero by approximately Days 60-80 and then went negative. By Day 70, VE/rVE was -25% (95% CI: -80 to 14) and 10% (95% CI: -32 to 39) for Doses 1 and 2 of ChAdOx1, respectively, and 42% (95% CI: 9 to 64) and 53% (95% CI: 26 to 70) for Doses 1 and 2 of BNT162b2, respectively. rVE for Dose 2 of BNT162b2 remained above zero throughout and reached 46% (95% CI: 13 to 67) after 98 days of follow-up.
      Conclusions: We found strong evidence of waning in VE/rVE for Doses 1 and 2 of ChAdOx1, as well as Dose 1 of BNT162b2. This evidence may be used to inform policies on timings of additional doses of vaccine.
      (© The Author(s) 2022. Published by Oxford University Press on behalf of the International Epidemiological Association.)
    • Grant Information:
      United Kingdom DH_ Department of Health; MC_PC_19075 United Kingdom MRC_ Medical Research Council; United Kingdom BHF_ British Heart Foundation; United Kingdom CSO_ Chief Scientist Office; MR/V028367/1 United Kingdom MRC_ Medical Research Council; MC_PC_20058 United Kingdom MRC_ Medical Research Council; United Kingdom WT_ Wellcome Trust
    • Contributed Indexing:
      Keywords: COVID-19; vaccine effectiveness; vaccine waning
    • الرقم المعرف:
      0 (BNT162 Vaccine)
      0 (COVID-19 Vaccines)
      0 (Smallpox Vaccine)
    • الموضوع:
      Date Created: 20221022 Date Completed: 20230210 Latest Revision: 20230921
    • الموضوع:
      20230921
    • الرقم المعرف:
      PMC9620314
    • الرقم المعرف:
      10.1093/ije/dyac199
    • الرقم المعرف:
      36272418